Purpose: Combretastatin A4 phosphate (CA4P) is a novel vascular targeting agent. Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) studies were performed to examine changes in parameters ...

Results: A similar pattern and time course of change in tumor and normal tissue parameters was seen in rats and humans. Rat tumor K trans was reduced by 64% 6 hours after treatment with CA4P (30 mg/kg ...